Nanotechnology in the diagnosis and management of heart, lung and blood diseases.
Heart, lung and blood diseases exert an enormous toll, accounting for almost half of the deaths in the USA each year. In addition to the morbidity and mortality resulting from these diseases, there is also a high economic burden, estimated at 560 billion US dollars for 2006. Nanotechnology offers a broad range of opportunities to improve diagnosis and therapy for cardiovascular, pulmonary and hematopoietic diseases, thereby decreasing these burdens. This review will focus on four areas of particular promise for the application of nanotechnology: imaging, diagnostics and biosensors, drug delivery and therapy, and tissue engineering and repair. The goal is to summarize the current state of science and technology in these areas and to look at future directions that the field is likely to move in to enhance the diagnosis and treatment of heart, lung and blood diseases.
Buxton
Denis B
DB
National Heart, Lung, & Blood Institute, Advanced Technologies & Surgery Branch, Division of Cardiovascular Diseases, Bethesda, MD 20892, USA. db225a@nih.gov
D000818:Animals; D006331:Heart Diseases / Q000175:diagnosis* / Q000191:economics / Q000401:mortality / Q000628:therapy; D006402:Hematologic Diseases / Q000175:diagnosis* / Q000191:economics / Q000401:mortality / Q000628:therapy; D006801:Humans; D008171:Lung Diseases / Q000175:diagnosis* / Q000191:economics / Q000401:mortality / Q000628:therapy; D036103:Nanotechnology / Q000191:economics / Q000639:trends